Browse > Article
http://dx.doi.org/10.14405/kjvr.2017.57.4.215

Temporal and subcellular distributions of Cy5.5-labeled hyaluronic acid nanoparticles in mouse organs during 28 days as a drug carrier  

Lin, Chunmei (College of Chinese Medicinal Materials, Jilin Agricultural University)
Kim, Saet Byeol (College of Veterinary Medicine and Veterinary Medical Center, Chungbuk National University)
Yon, Jung-Min (College of Veterinary Medicine and Veterinary Medical Center, Chungbuk National University)
Park, Seul Gi (College of Veterinary Medicine and Veterinary Medical Center, Chungbuk National University)
Gwon, Lee Wha (College of Veterinary Medicine and Veterinary Medical Center, Chungbuk National University)
Lee, Jong-Geol (College of Veterinary Medicine and Veterinary Medical Center, Chungbuk National University)
Baek, In-Jeoung (Asan Institute for Life Sciences, Asan Medical Center and University of Ulsan)
Lee, Beom Jun (College of Veterinary Medicine and Veterinary Medical Center, Chungbuk National University)
Yun, Young Won (College of Veterinary Medicine and Veterinary Medical Center, Chungbuk National University)
Nam, Sang-Yoon (College of Veterinary Medicine and Veterinary Medical Center, Chungbuk National University)
Publication Information
Korean Journal of Veterinary Research / v.57, no.4, 2017 , pp. 215-222 More about this Journal
Abstract
Temporal and subcellular distributions of hyaluronic acid (HA) as a degradable nanoparticle (NP) in animals were investigated to determine if HA-NP could be utilized as an appropriate drug delivery system. After mice were intravenously injected with 5 mg/kg of Cy5.5-labeled HA-NP sized 350-400 nm or larger HA-polymers, the fluorescence intensity was measured in all homogenized organs from 0.5 h to 28 days. HA-NP was greatly detected in spleen, liver and kidney until day 28, while it was maintained at low levels in other organs. HA-polymer was observed at low levels in all organs. HA-NP quantities in spleen and liver were reduced until day 3, but increased sharply between days 3 and 7, then decreased again, while their HA-polymers were maintained at low levels until day 28. In kidneys, both HA-NP and HA-polymer showed high levels after 0.5 h of administration, but steadily decreased until day 28. According to ultrastructural analyses, HA-NP was engulfed in Kupffer cells of liver and macrophages of spleen and kidney at day 1 and was accumulated in the cytoplasm of kidney tubular cells at day 7. Overall, these findings suggest that HA-NP could be considered a desirable drug carrier in the liver, kidney, or spleen.
Keywords
drug delivery systems; hyaluronic acid; nanoparticles; pharmacokinetics; subcellular localization;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Jain KK. Current status and future prospects of drug delivery systems. Methods Mol Biol 2014, 1141, 1-56.
2 Kakehi K, Kinoshita M, Yasueda S. Hyaluronic acid: separation and biological implications. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 797, 347-355.   DOI
3 Kim YS, Kim JS, Cho HS, Rha DS, Kim JM, Park JD, Choi BS, Lim R, Chang HK, Chung YH, Kwon IH, Jeong J, Han BS, Yu IJ. Twenty-eight-day oral toxicity, genotoxicity, and gender-related tissue distribution of silver nanoparticles in Sprague-Dawley rats. Inhal Toxicol 2008, 20, 575-583.   DOI
4 Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science 1998, 280, 1036-1037.   DOI
5 Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010, 75, 1-18.   DOI
6 Lankveld DPK, Oomen AG, Krystek P, Neigh A, Troostde Jong A, Noorlander CW, Van Eijkeren JCH, Geertsma RE, De Jong WH. The kinetics of the tissue distribution of silver nanoparticles of different sizes. Biomaterials 2010, 31, 8350-8361.   DOI
7 Lap ik L Jr, Lap ik L, De Smedt S, Demeester J, Chabre ek P. Hyaluronan: preparation, structure, properties, and applications. Chem Rev 1998, 98, 2663-2684.   DOI
8 Lee H, Lee K, Park TG. Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity. Bioconjug Chem 2008, 19, 1319-1325.   DOI
9 Lee MJE, Veiseh O, Bhattarai N, Sun C, Hansen SJ, Ditzler S, Knoblaugh S, Lee D, Ellenbogen R, Zhang M, Olson JM. Rapid pharmacokinetic and biodistribution studies using cholorotoxin-conjugated iron oxide nanoparticles: a novel non-radioactive method. PLoS One 2010, 5, e9536.   DOI
10 Ma HL, Xu YF, Qi XR, Maitani Y, Nagai T. Superparamagnetic iron oxide nanoparticles stabilized by alginate: pharmacokinetics, tissue distribution, and applications in detecting liver cancers. Int J Pharm 2008, 354, 217-226.   DOI
11 Mironov V, Kasyanov V, Zheng Shu X, Eisenberg C, Eisenberg L, Gonda S, Trusk T, Markwald RR, Prestwich GD. Fabrication of tubular tissue constructs by centrifugal casting of cells suspended in an in situ crosslinkable hyaluronan-gelatin hydrogel. Biomaterials 2005, 26, 7628-7635.   DOI
12 Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2, 751-760.   DOI
13 Peer D, Margalit R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer 2004, 108, 780-789.   DOI
14 Platt VM, Szoka FC Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 2008, 5, 474-486.   DOI
15 Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001, 70, 1-20.   DOI
16 Tamaki S, Ueno T, Torimura T, Sata M, Tanikawa K. Evaluation of hyaluronic acid binding ability of hepatic sinusoidal endothelial cells in rats with liver cirrhosis. Gastroenterology 1996, 111, 1049-1057.   DOI
17 Yang RS, Chang LW, Wu JP, Tsai MH, Wang HJ, Kuo YC, Yeh TK, Yang CS, Lin P. Persistent tissue kinetics and redistribution of nanoparticles, quantum dot 705, in mice: ICP-MS quantitative assessment. Environ Health Perspect 2007, 115, 1339-1343.   DOI
18 Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004, 4, 528-539.   DOI
19 Wang J, Zhou G, Chen C, Yu H, Wang T, Ma Y, Jia G, Gao Y, Li B, Sun J, Li Y, Jiao F, Zhao Y, Chai Z. Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration. Toxicol Lett 2007, 168, 176-185.   DOI
20 Xie G, Sun J, Zhong G, Shi L, Zhang D. Biodistribution and toxicity of intravenously administered silica nanoparticles in mice. Arch Toxicol 2010, 84, 183-190.   DOI
21 Zhou B, Weigel JA, Fauss L, Weigel PH. Identification of the hyaluronan receptor for endocytosis (HARE). J Biol Chem 2000, 275, 37733-37741.   DOI
22 Choi KY, Chung H, Min KH, Yoon HY, Kim K, Park JH, Kwon IC, Jeong SY. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 2010, 31, 106-114.   DOI
23 Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5, 505-515.   DOI
24 Balazs EA, Denlinger JL. Clinical uses of hyaluronan. Ciba Found Symp1989, 143, 265-275.
25 Bazile D, Prud'homme C, Bassoullet MT, Marlard M, Spenlehauer G, Veillard M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci 1995, 84, 493-498.   DOI
26 De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJAM, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 2008, 29, 1912-1919.   DOI
27 He Q, Zhang Z, Gao F, Li Y, Shi J. In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. Small 2011, 7, 271-280.   DOI
28 Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5, 161-171.   DOI
29 Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100, 57-70.   DOI